Single-Dose Solosec Approved for Trichomoniasis
Since trichomoniasis is a sexually transmitted disease, sexual partners should be treated with the same dose and at the same time.
Women’s Health
Myfembree Now Available for Heavy Menstrual Bleeding With Uterine Fibroids
Myfembree consists of relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.
Severe Abnormal Uterine Bleeding Risk With Anticoagulant Therapy Examined
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.
Brexafemme Approved for Vulvovaginal Candidiasis
The approval was based on data from two phase 3 trials that compared Brexafemme to placebo in female patients aged 12 years and older with acute VVC.
Myfembree Approved for Heavy Menstrual Bleeding With Uterine Fibroids
Myfembree is a combination of relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.
CDC: Self-Administered Subcutaneous DMPA Should Be Made Available
WHO recommendation adopted based on evidence that self-administered DMPA-SC is safe, effective with higher continuation rates
Vaginal pH Regulator Gets Fast Track Status for Gonorrhea Prevention
EVO100 is pH-modulating vaginal gel designed to reduce certain vaginal infections by balancing vaginal pH, thereby maintaining healthy vaginal flora.
Novel Contraceptive Nextstellis Gets FDA Approval
Nextstellis is a novel combined oral contraceptive pill containing drospirenone 3mg (DRSP) and estetrol 14.2mg.
Pessary Treatment Successful for Symptomatic Pelvic Organ Prolapse
75.3 percent of patients report successful pessary treatment at five-year follow-up, with discontinuation rates decreasing over time
Relugolix Combo Therapy Beneficial for Fibroid-Related Menorrhagia
Significantly more women had reduced menstrual bleeding with once-daily relugolix combination therapy versus placebo
